MED11

Summary

MED11 (mediator complex subunit 11, HGNC:32687) is a protein-coding gene on chromosome 17p13.2, encoding Mediator of RNA polymerase II transcription subunit 11 (Q9P086). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. It is a common-essential gene (DepMap: required in 100.0% of cancer cell lines).

MED11 is a component of the Mediator complex, which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (Sato et al., 2003 [PubMed 12584197]).

Source: NCBI Gene 400569 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities (Strong, GenCC)
• Clinical variants (ClinVar): 23 total — 1 pathogenic
• Phenotypes (HPO): 27
• Cancer dependency (DepMap): dependent in 100.0% of screened cell lines (common-essential)
• MANE Select transcript: NM_001001683

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32687
Approved symbol	MED11
Name	mediator complex subunit 11
Location	17p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HSPC296, MGC88387
Ensembl gene	ENSG00000161920
Ensembl biotype	protein_coding
OMIM	612383
Entrez	400569

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000293777, ENST00000573708, ENST00000575284, ENST00000674339, ENST00000886211

RefSeq mRNA: 2 — MANE Select: NM_001001683 NM_001001683, NM_001305000

CCDS: CCDS32533, CCDS76920

Canonical transcript exons

ENST00000293777 — 3 exons

Exon	Start	End
ENSE00001061366	4731428	4731574
ENSE00001061367	4731776	4731906
ENSE00001231283	4733050	4733607

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 93.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.2581 / max 162.6621, expressed in 1785 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158927	12.2581	1785

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland	UBERON:0001233	93.15	gold quality
right adrenal gland cortex	UBERON:0035827	92.87	gold quality
left adrenal gland	UBERON:0001234	92.35	gold quality
left adrenal gland cortex	UBERON:0035825	92.18	gold quality
upper arm skin	UBERON:0004263	92.07	gold quality
adrenal cortex	UBERON:0001235	92.02	gold quality
granulocyte	CL:0000094	91.76	gold quality
apex of heart	UBERON:0002098	91.66	gold quality
left ventricle myocardium	UBERON:0006566	91.54	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.51	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.37	silver quality
mucosa of transverse colon	UBERON:0004991	90.98	gold quality
kidney epithelium	UBERON:0004819	90.96	gold quality
deltoid	UBERON:0001476	90.93	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.81	gold quality
adrenal gland	UBERON:0002369	90.59	gold quality
ileal mucosa	UBERON:0000331	90.57	gold quality
body of stomach	UBERON:0001161	90.55	gold quality
gastrocnemius	UBERON:0001388	90.41	gold quality
spleen	UBERON:0002106	90.37	gold quality
myocardium	UBERON:0002349	90.35	gold quality
muscle of leg	UBERON:0001383	90.18	gold quality
right lobe of liver	UBERON:0001114	90.10	gold quality
adult mammalian kidney	UBERON:0000082	90.08	gold quality
spinal cord	UBERON:0002240	90.05	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.99	gold quality
tibialis anterior	UBERON:0001385	89.87	gold quality
blood	UBERON:0000178	89.84	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.44	gold quality
oocyte	CL:0000023	89.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting MED11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-5584-3P	99.23	68.79	1351
HSA-MIR-4795-5P	99.11	66.90	876
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-92A-1-5P	98.28	64.51	631
HSA-MIR-6787-3P	97.75	66.17	1233
HSA-MIR-6841-5P	97.19	67.29	409
HSA-MIR-3907	96.76	65.04	662
HSA-MIR-5704	94.82	67.46	448
HSA-MIR-4734	88.28	63.44	87

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 100.0% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• A homozygous MED11 C-terminal variant causes a lethal neurodegenerative disease. (PMID:36001086)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	med11	ENSDARG00000086416
mus_musculus	Med11	ENSMUSG00000018923
rattus_norvegicus	Med11	ENSRNOG00000019384
drosophila_melanogaster	MED11	FBGN0036811
caenorhabditis_elegans		WBGENE00007015

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 11 — Q9P086 (reviewed: Q9P086)

Alternative names: Mediator complex subunit 11

All UniProt accessions (4): A0A6I8PLG6, Q9P086, I3L2Q0, I3L3E8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors.

Subunit / interactions. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP.

Subcellular location. Nucleus.

Disease relevance. Neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities (NDDRSB) [MIM:620327] An autosomal recessive disorder characterized by congenital microcephaly, profound global developmental delay, exaggerated startle response, refractory myoclonic seizures, progressive widespread neurodegeneration, and premature death. The disease may be caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the Mediator complex subunit 11 family.

RefSeq proteins (2): NP_001001683, NP_001291929 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019404	Mediator_Med11	Family

Pfam: PF10280

UniProt features (9 total): helix 3, initiator methionine 1, chain 1, modified residue 1, sequence variant 1, sequence conflict 1, strand 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
7EMF	ELECTRON MICROSCOPY	3.5
8TRH	ELECTRON MICROSCOPY	3.7
7ENA	ELECTRON MICROSCOPY	4.07
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7ENJ	ELECTRON MICROSCOPY	4.4
7NVR	ELECTRON MICROSCOPY	4.5
8T9D	ELECTRON MICROSCOPY	4.66
7LBM	ELECTRON MICROSCOPY	4.8
8GXQ	ELECTRON MICROSCOPY	5.04
8TQW	ELECTRON MICROSCOPY	8.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P086-F1	87.78	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways
R-HSA-9843745	Adipogenesis

MSigDB gene sets: 191 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, TGCGCANK_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, CHANDRAN_METASTASIS_DN, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX, GOCC_TRANSFERASE_COMPLEX, BENPORATH_OCT4_TARGETS

GO Biological Process (5): protein ubiquitination (GO:0016567), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (3): transcription coregulator activity (GO:0003712), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515)

GO Cellular Component (5): ubiquitin ligase complex (GO:0000151), nucleus (GO:0005634), nucleoplasm (GO:0005654), mediator complex (GO:0016592), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Metabolism of lipids	1
Metabolism	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of transcription by RNA polymerase II	2
transcription initiation at RNA polymerase II promoter	2
protein modification by small protein conjugation	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
transcription preinitiation complex assembly	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
transcription regulator activity	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
intracellular protein-containing complex	1
transferase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
core mediator complex	1
nuclear protein-containing complex	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

688 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED11	MED22	Q15528	999
MED11	MED18	Q9BUE0	998
MED11	MED17	Q9NVC6	995
MED11	MED8	Q96G25	995
MED11	MED6	O75586	994
MED11	MED30	Q96HR3	987
MED11	MED20	Q9H944	984
MED11	MED10	Q9BTT4	974
MED11	MED27	Q6P2C8	953
MED11	MED19	A0JLT2	948
MED11	MED14	O60244	886
MED11	MED7	O43513	869
MED11	MED21	Q13503	823
MED11	MED29	Q9NX70	819
MED11	MED31	Q9Y3C7	772

IntAct

126 interactions, top by confidence:

A	B	Type	Score
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
MED10	MED6	psi-mi:“MI:0914”(association)	0.870
MED17	MED22	psi-mi:“MI:0914”(association)	0.860
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
MED18	MED19	psi-mi:“MI:0914”(association)	0.840
MED31	MED19	psi-mi:“MI:0914”(association)	0.840
MED7	MED19	psi-mi:“MI:0914”(association)	0.840
MED11	MED19	psi-mi:“MI:0914”(association)	0.840

BioGRID (197): MED11 (Affinity Capture-MS), MED11 (Affinity Capture-MS), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED11 (Co-fractionation), MED16 (Co-fractionation), MED17 (Co-fractionation)

ESM2 similar proteins: A3KNK7, A4QP78, A4VCH4, A8E5U3, A9ULY7, G0RY74, O95295, P60192, Q0IHI6, Q13503, Q178E6, Q17NH9, Q28HX4, Q2HJG5, Q2M146, Q2TBU8, Q3B8I4, Q40554, Q4R6N3, Q5EA95, Q5PPY2, Q5PQM2, Q5RE46, Q68EW7, Q6DGZ3, Q6GPR9, Q6ID77, Q6IVW0, Q6P255, Q6PC45, Q7QB45, Q7ZTI5, Q8BXG3, Q8LCH5, Q8VD75, Q96HR3, Q96QK1, Q99LM2, Q9CQ39, Q9CQI9

Diamond homologs: A3KNK7, Q17NH9, Q32L03, Q612X6, Q68EW7, Q6P255, Q9BI74, Q9D8C6, Q9P086, Q9VVS4

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MED11	“form complex”	“Core mediator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 50 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	25	126.2×	3e-48
RSV-host interactions	25	100.3×	1e-45
Adipogenesis	25	100.3×	1e-45
Regulation of lipid metabolism by PPARalpha	25	90.4×	2e-44
Transcriptional regulation of white adipocyte differentiation	25	83.2×	2e-43
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	15	82.9×	5e-25
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	15	75.7×	2e-24
Epigenetic regulation by WDR5-containing histone modifying complexes	16	63.3×	1e-24

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	21	137.4×	9e-40
positive regulation of transcription initiation by RNA polymerase II	22	130.0×	7e-41
RNA polymerase II preinitiation complex assembly	21	124.1×	8e-39
somatic stem cell population maintenance	10	53.9×	1e-13
transcription initiation at RNA polymerase II promoter	5	40.7×	5e-06
protein ubiquitination	10	9.0×	5e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	20
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2499501	NM_001001683.4(MED11):c.325C>T (p.Arg109Ter)	Pathogenic

SpliceAI

466 predictions. Top by Δscore:

Variant	Effect	Δscore
17:4731603:G:GT	donor_gain	1.0000
17:4731904:CAGGT:C	donor_loss	1.0000
17:4731906:GGTC:G	donor_loss	1.0000
17:4731907:G:GA	donor_loss	1.0000
17:4731532:G:GT	donor_gain	0.9900
17:4731570:TGCAG:T	donor_loss	0.9900
17:4731572:C:T	donor_gain	0.9900
17:4731572:CAG:C	donor_loss	0.9900
17:4731573:AGGTT:A	donor_loss	0.9900
17:4731574:GG:G	donor_loss	0.9900
17:4731575:GTTC:G	donor_loss	0.9900
17:4731576:T:A	donor_loss	0.9900
17:4731603:G:T	donor_gain	0.9900
17:4731645:G:GT	donor_gain	0.9900
17:4731645:G:T	donor_gain	0.9900
17:4731612:GC:G	donor_gain	0.9800
17:4731657:GGT:G	donor_gain	0.9700
17:4731631:G:GT	donor_gain	0.9600
17:4731547:G:T	donor_gain	0.9500
17:4731581:G:GT	donor_gain	0.9500
17:4731617:ACCGG:A	donor_gain	0.9500
17:4731659:TTGGG:T	donor_gain	0.9500
17:4731905:AGGTC:A	donor_gain	0.9500
17:4731765:C:A	acceptor_gain	0.9400
17:4731609:A:T	donor_gain	0.9300
17:4731656:GG:G	donor_gain	0.9300
17:4731660:T:A	donor_gain	0.9200
17:4731547:G:GT	donor_gain	0.9100
17:4731618:C:G	donor_gain	0.9100
17:4731650:G:GT	donor_gain	0.9100

AlphaMissense

745 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:4731878:T:C	L63P	0.999
17:4731899:T:A	L70H	0.999
17:4731899:T:C	L70P	0.999
17:4733054:C:A	A74D	0.999
17:4733074:G:C	G81R	0.999
17:4731572:C:A	A28E	0.998
17:4731845:T:C	F52S	0.998
17:4731890:T:C	I67T	0.998
17:4733068:C:G	H79D	0.998
17:4733074:G:T	G81C	0.998
17:4733083:T:C	Y84H	0.998
17:4731530:T:A	L14Q	0.997
17:4731530:T:C	L14P	0.997
17:4731844:T:C	F52L	0.997
17:4731846:C:A	F52L	0.997
17:4731846:C:G	F52L	0.997
17:4731890:T:G	I67S	0.997
17:4733053:G:C	A74P	0.997
17:4733070:T:A	H79Q	0.997
17:4733070:T:G	H79Q	0.997
17:4733110:G:C	A93P	0.997
17:4731521:T:C	L11P	0.996
17:4731542:A:T	E18V	0.996
17:4731563:T:C	L25P	0.996
17:4731776:G:A	G29D	0.996
17:4731790:G:A	E34K	0.996
17:4731878:T:A	L63Q	0.996
17:4731895:T:G	Y69D	0.996
17:4733057:C:T	T75I	0.996
17:4733068:C:A	H79N	0.996

dbSNP variants (sampled 300 via entrez): RS1000820610 (17:4732275 T>G), RS1000851633 (17:4732015 C>A,G,T), RS1001370188 (17:4730321 G>A), RS1001427583 (17:4730929 A>G), RS1001903939 (17:4733481 G>C), RS1004606929 (17:4733599 CAA>C), RS1004749670 (17:4733866 T>A), RS1005723565 (17:4733403 C>G), RS1008026917 (17:4729835 G>A), RS1008741128 (17:4731230 T>C), RS1009547255 (17:4732620 T>C), RS1009743795 (17:4732338 G>A,C,T), RS1011615704 (17:4730229 G>C), RS1012025070 (17:4733572 TAAA>T), RS1013045462 (17:4730817 A>G)

Disease associations

OMIM: gene MIM:612383 | disease phenotypes: MIM:620327

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities	Strong	Autosomal recessive

Mondo (1): neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities (MONDO:0957225)

Orphanet (0):

HPO phenotypes

27 total (27 of 27 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000126	Hydronephrosis
HP:0000365	Hearing impairment
HP:0000486	Strabismus
HP:0000518	Cataract
HP:0000639	Nystagmus
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001321	Cerebellar hypoplasia
HP:0001337	Tremor
HP:0001511	Intrauterine growth retardation
HP:0001631	Atrial septal defect
HP:0001643	Patent ductus arteriosus
HP:0001655	Patent foramen ovale
HP:0002120	Cerebral cortical atrophy
HP:0002267	Exaggerated startle response
HP:0002380	Fasciculations
HP:0002509	Limb hypertonia
HP:0002878	Respiratory failure
HP:0003121	Limb joint contracture
HP:0003577	Congenital onset
HP:0007068	Inferior cerebellar vermis hypoplasia
HP:0008936	Axial hypotonia
HP:0012444	Brain atrophy
HP:0032398	Dysgyria
HP:0032794	Myoclonic seizure

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
bleomycetin	decreases expression	1
potassium chromate(VI)	decreases expression, affects cotreatment	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
STA 9090	increases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants, Occupational	decreases expression	1
Amiodarone	increases expression	1
Diuron	decreases expression	1
Doxorubicin	increases expression	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Nickel	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Thiram	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	affects expression	1
Vanadates	decreases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	decreases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.